Wolverine Asset Management’s Japer Therapeutics Warrants JSPRW Stock Holding History

Wolverine Asset Management’s Portfolio JSPRW Stock Details JSPRW Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$22	Buy	1,639 +600	+58%	+$9	﹤0.01%	1659
2026 Q1	$23	Buy	+1,039	New	+$34	﹤0.01%	1669
2023 Q1	–	Sell	-10,646	Closed	-$319	–	1990
2022 Q4	$319	Hold	10,646	–	–	﹤0.01%	2015
2022 Q3	$0	Buy	10,646 +2,317	+28%	+$202	﹤0.01%	2440
2022 Q2	$0	Hold	8,329	–	–	﹤0.01%	2393
2022 Q1	$2K	Sell	8,329 -65	-0.8%	-$36	﹤0.01%	2083
2021 Q4	$12K	Buy	+8,394	New	+$11.7K	﹤0.01%	1818
2021 Q2	–	Sell	-60	Closed	–	–	2294
2021 Q1	$0	Buy	+60	New	+$88	﹤0.01%	2149
2020 Q3	–	Sell	-72,772	Closed	-$72K	–	1662
2020 Q2	$72K	Buy	72,772 +17,772	+32%	+$11.1K	﹤0.01%	1152
2020 Q1	$35K	Buy	+55,000	New	+$43.2K	﹤0.01%	1217

Other funds holding JSPRW

BFM

Boothbay Fund Management New York $7.6B AUM 109.3% 1-Year Est. Return

Toronto Dominion Bank Toronto, Ontario, Ontario, Canada $86.4B AUM 59.51% 1-Year Est. Return

TCM

Tenor Capital Management New York $7.09B AUM 3.55% 1-Year Est. Return

Walleye Capital New York $28B AUM 44.22% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

Wolverine Asset Management's JSPRW Position: Q2 2026 in Review

Wolverine Asset Management increased its Japer Therapeutics Warrants (JSPRW) stake by 58% in Q2 2026, buying an estimated $9 and bringing the position to 1,639 shares worth $22. The position accounts for ﹤0.01% of the portfolio, ranked #1659.

Wolverine Asset Management first reported a position in JSPRW in Q1 2020 and has held it in 10 quarters since. The position peaked at $72K in Q2 2020. 6 funds tracked by Wall St. Rank hold JSPRW as of Q2 2026.

Wolverine Asset Management held 1,639 shares of Japer Therapeutics Warrants worth $22 as of Q2 2026.
Wolverine Asset Management bought 600 Japer Therapeutics Warrants shares in Q2 2026, an estimated $9.
Japer Therapeutics Warrants made up ﹤0.01% of Wolverine Asset Management's portfolio in Q2 2026, its #1659 holding.
Wolverine Asset Management first reported a position in Japer Therapeutics Warrants in Q1 2020 and has held it in 10 quarters since.
Wolverine Asset Management's Japer Therapeutics Warrants position peaked at $72K in Q2 2020.
6 funds tracked by Wall St. Rank held Japer Therapeutics Warrants as of Q2 2026.

Based on Wolverine Asset Management's 13F filing for Q2 2026, filed 10 Aug 2026.